Immunotherapy in Ovarian Cancer

Volume 1 - Issue 3

Satyendra C Tripathi*

Received: January 10, 2018;   Published: January 24, 2018

DOI: 10.32474/IGWHC.2018.01.000112

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Ovarian cancer ranks fifth with a 5-year survival of 40% for patients with advanced disease and remains the most lethal gynecologic malignancy among women [1]. Most patients with advanced disease undergo aggressive frontline treatments with surgery and adjuvant chemotherapy; however, 80% of patients ultimately recur within few months and develop chemoresistant disease [2]. Advances in traditional treatment regimens and addition bevacizumab as a targeted therapy have shown promising results with improved progression-free survival but overall survival rates still remains the unaltered.

Editorial| References|